Article Type
Changed
Tue, 10/31/2023 - 12:07

Key clinical point: Comparable prevalence rates of non-alcoholic fatty liver disease (NAFLD) in patients with moderate-to-severe atopic dermatitis (AD) and those with in situ melanoma suggest that AD is not a risk factor for NAFLD.

Major finding: The prevalence rate of NAFLD was similar in patients with AD (24.1%) and those with in situ melanoma (23.2%), but it was significantly higher in patients with moderate-to-severe chronic plaque psoriasis (49.8%) compared with the other two groups (both P < .01). AD was not independently associated with NAFLD (adjusted odds ratio 1.02; 95% CI 0.78-1.26).

Study details: Findings are from a retrospective cross-sectional study including adult patients with moderate-to-severe AD (n = 144), moderate-to-severe chronic plaque psoriasis (n = 466), or in situ melanoma (n = 99).

Disclosures: This study was funded by European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and Strengthening of Biomedical Research in the National Health Service. The authors declared no conflicts of interest.

Source: Maurelli M et al. Prevalence of non-alcoholic fatty liver disease in adult individuals with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(18):6057 (Sep 19). doi: 10.3390/jcm12186057

 

Publications
Topics
Sections

Key clinical point: Comparable prevalence rates of non-alcoholic fatty liver disease (NAFLD) in patients with moderate-to-severe atopic dermatitis (AD) and those with in situ melanoma suggest that AD is not a risk factor for NAFLD.

Major finding: The prevalence rate of NAFLD was similar in patients with AD (24.1%) and those with in situ melanoma (23.2%), but it was significantly higher in patients with moderate-to-severe chronic plaque psoriasis (49.8%) compared with the other two groups (both P < .01). AD was not independently associated with NAFLD (adjusted odds ratio 1.02; 95% CI 0.78-1.26).

Study details: Findings are from a retrospective cross-sectional study including adult patients with moderate-to-severe AD (n = 144), moderate-to-severe chronic plaque psoriasis (n = 466), or in situ melanoma (n = 99).

Disclosures: This study was funded by European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and Strengthening of Biomedical Research in the National Health Service. The authors declared no conflicts of interest.

Source: Maurelli M et al. Prevalence of non-alcoholic fatty liver disease in adult individuals with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(18):6057 (Sep 19). doi: 10.3390/jcm12186057

 

Key clinical point: Comparable prevalence rates of non-alcoholic fatty liver disease (NAFLD) in patients with moderate-to-severe atopic dermatitis (AD) and those with in situ melanoma suggest that AD is not a risk factor for NAFLD.

Major finding: The prevalence rate of NAFLD was similar in patients with AD (24.1%) and those with in situ melanoma (23.2%), but it was significantly higher in patients with moderate-to-severe chronic plaque psoriasis (49.8%) compared with the other two groups (both P < .01). AD was not independently associated with NAFLD (adjusted odds ratio 1.02; 95% CI 0.78-1.26).

Study details: Findings are from a retrospective cross-sectional study including adult patients with moderate-to-severe AD (n = 144), moderate-to-severe chronic plaque psoriasis (n = 466), or in situ melanoma (n = 99).

Disclosures: This study was funded by European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and Strengthening of Biomedical Research in the National Health Service. The authors declared no conflicts of interest.

Source: Maurelli M et al. Prevalence of non-alcoholic fatty liver disease in adult individuals with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(18):6057 (Sep 19). doi: 10.3390/jcm12186057

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan, Atopic Dermatitis November 2023
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article